Abstract: The present invention relates to compositions comprising nucleobases and/or sources of nucleobases and polysaccharides from extracts of fungi, yeasts or bacteria. Preferably, the compositions include Nucleoforce® or Nucleoforce® Dogs and AHCC®. Said compositions are useful in the treatment and prevention of immunosuppression, of the toxicity derived from chemotherapy or radiotherapy treatment, of diseases of the immune system, of cancer or an infection; and are also useful to stimulate the immune function in a mammal, including a human.
Type:
Grant
Filed:
September 8, 2009
Date of Patent:
October 20, 2015
Assignee:
Bioiberica, S.A.
Inventors:
Josep Escaich Ferrer, Daniel Martinez Puig, Carles Chetrit Russi, Elisabet Borda Casas, Ken-ichi Kosuna
Abstract: The present invention includes methods for effecting phenotype conversion in a cell by transfecting the cell with phenotype-converting nucleic acid. Expression of the nucleic acids results in a phenotype conversion in the transfected cell. Preferably the phenotype-converting nucleic acid is a transcriptome, and more preferably an mRNA transcriptome.
Type:
Grant
Filed:
July 19, 2011
Date of Patent:
October 13, 2015
Assignee:
The Trustees of the University of Pennsylvania
Inventors:
James Eberwine, Jai-Yoon Sul, Tae Kyung Kim, Vickas Patel
Abstract: Methods of treatment of diseases that include or are characterized by inappropriate or pathological neovascularization are disclosed. These diseases include diseases of the eye, such as diabetic retinopathy, retinopathy of prematurity, and choroidal neovascularization which can occur in age-related macular degeneration (AMD). Disclosed methods include administering agents that cause directly or indirectly upregulation of the ABCA1 transporter protein in macrophages. These agents include, without limitation, LXR agonists. In some embodiments, inhibitors of CETP expression or activity can also be effective. Administration routes can include, without limitation, intraocular, periocular, or systemic administration.
Abstract: Method for modulating or controlling sodium channel current of a cell includes inducing mitochondrial reactive oxygen species (ROS) production in the cell.
Type:
Grant
Filed:
February 16, 2011
Date of Patent:
August 25, 2015
Assignees:
THE UNITED STATES OF AMERICA DEPT. OF VETERANS AFFAIRS, THE BOARD OF TRUSTEES OF THE UNIV. OF ILLINOIS
Abstract: The present invention relates to the identification of polynucleotides and polypeptides involved in insulin and adiponectin signaling and regulation of glucose production. The invention further relates to the use of the identified polynucleotides and polypeptides, and inhibitors of the polynucleotides and polypeptides, in the regulation of glucose production and the monitoring and treatment of metabolic disorders such as diabetes.
Type:
Grant
Filed:
September 6, 2013
Date of Patent:
August 11, 2015
Assignee:
The University of North Carolina at Chapel Hill
Abstract: The disclosed methods pertain to diagnosing whether a non-ablative, gene therapy is needed for reducing AF fibrosis in a subject, and if so, methods of reducing AF fibrosis in a subject using gene therapy with a dominant negative TGF-? R2 cDNA expression vector. Kits and computer program products are also described, wherein the kits provide materials for diagnosing and treating AF fibrosis, and the computer program products include a computer readable medium having computer readable program code for monitoring the efficacy of therapeutic ablation of fibrosis in a subject using a gene therapy method.
Abstract: In one aspect the present invention relates to pharmaceutical kits of parts suitable for treating neoplastic diseases such as cancer comprising an anti-cancer medicament, a Basidiomycete bioactive agent in solid or liquid form, and, optionally instructions for a dosing regime.
Abstract: The invention provides methods for depleting extraneous phenotypes from a mixed population of cells comprising the in vitro differentiated progeny of primate pluripotent stem cells. The invention also provides mixed cell populations enriched for a target cell phenotype where the mixed cell population comprises the differentiated in vitro progeny of primate embryonic stem cells.
Type:
Grant
Filed:
November 16, 2012
Date of Patent:
July 7, 2015
Assignee:
Asterias Biotherapeutics, Inc.
Inventors:
Jane S. Lebkowski, Catherine Ann Priest, Ross M. Okamura
Abstract: Bacteria which co-express protease inhibitors and protease sensitive therapeutic agents, which are surface displayed, secreted and/or released and result in their localized production and maintenance within a target tissue and inactivation outside of the target tissue, thereby increasing therapeutic activity and reducing the systemic toxicity. The bacteria may be attenuated, non-pathogenic, low pathogenic or a probiotic. Protease sensitivity may be further accomplished by engineering protease degradation sites within the therapeutic agents, further enhancing the inactivation outside of the target tissue while retaining activity within the target tissue through co-expression of a protease inhibitor. Novel chimeric proteins secreted by bacteria, including chimeric toxins targeted to neoplastic cells, tumor matrix cells and cells of the immune system, and combination therapies of these protease inhibitor:chimeric toxin-expressing bacteria together with small-molecule and biologic agents are also described.
Abstract: Disclosed is a cell which can express a non-natural oligomeric protein, which has, introduced therein, a gene encoding an exogenous polypeptide corresponding to at least one endogenous polypeptide constituting a natural oligomeric protein, and in which the expression of the endogenous polypeptide is inhibited.
Abstract: A mechanism for increasing resistance to Enterobacteriaceae infection is described. Additionally genetic markers for identifying traits associated with resistance to Enterobacteriaceae are also described. Thus the invention provides methods and compositions for the production of animals which exhibit increased resistance to Enterobacteriaceae infection. The invention further provides methods and compositions for marker assisted breeding to identify animals resistant to Enterobacteriaceae infection. The invention allows for cattle production with lower susceptibility to Enterobacteriaceae infection.
Abstract: A method of modulating or controlling connexin 43 (Cx43) level of a cell includes inducing mitochondrial reactive oxygen species (ROS) production in the cell.
Type:
Grant
Filed:
June 21, 2012
Date of Patent:
June 9, 2015
Assignees:
U.S. DEPARTMENT OF VETERANS AFFAIRS, THE BOARD OF TRUSTEES OF THE UNIV. OF ILLINOIS
Abstract: The present invention relates to an isolated nucleic acid molecule comprising a first nucleotide sequence encoding a protein that detects the presence, amount or both of a pathogenic microorganism by forming a complex with a protein produced by said pathogenic microorganism; a second nucleotide sequence encoding an antimicrobial peptide, wherein the antimicrobial peptide is effective against the pathogenic microorganism detected by the protein encoded by the first nucleotide sequence, wherein the second nucleotide sequence is under control of a promoter that is induced by the complex of the protein encoded by the first nucleotide sequence and the protein produced by said pathogenic microorganism. A recombinant microorganism comprising the isolated nucleic acid molecule and a method of sensing and killing pathogenic microorganisms is also described.
Type:
Grant
Filed:
August 15, 2012
Date of Patent:
June 2, 2015
Assignee:
Nanyang Technological University
Inventors:
Matthew Wook Chang, Chueh Loo Poh, Choon Kit Wong, Nazanin Saeidi
Abstract: The present invention relates to a method for identifying an inhibitor of the aggregation of amyloid-? peptide (A?), comprising the steps of a) contacting at least one A? -peptide and/or the nitrated forms thereof with at least one candidate inhibitor that potentially specifically binds to a region in said A? -peptide capable of being nitrated, and b) detecting said inhibitor specifically binding to said region in said A? -peptide through detecting a lack of or a reduced aggregation of said at least one A? -peptide. The present invention is further directed at improved methods for treating neuronal degradation and particularly Alzheimer's disease, based on said inhibitor. The present invention is further directed at methods for diagnosing the aggregation of A? -peptide in the context of neuronal degradation and particularly Alzheimer's disease.
Abstract: Disclosed is a method for amplifying RNA and/or DNA from immune cell populations and using the amplified products to produce an immune response profile and evaluate the possible correlation between a normal or abnormal immune response and the development of a disease such as an autoimmune disease, cancer, diabetes, or heart disease.
Abstract: Described herein is the generation of Fah+/? heterozygote pigs by homologous recombination and somatic cell nuclear transfer, and a method for producing Fah?/? homozygote pigs. The Fah-deficient pigs of the disclosure can be used for a variety of research and therapeutic purposes, such as for the expansion of human hepatocytes, and as large animal models of hereditary tyrosinemia type 1, cirrhosis and hepatocellular carcinoma.
Type:
Grant
Filed:
March 23, 2011
Date of Patent:
April 7, 2015
Assignees:
Oregon Health & Science University, Mayo Foundation for Medical Education and Research
Inventors:
Markus Grompe, Scott Nyberg, Joseph Lillegard, Raymond Hickey
Abstract: Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of stem cells. Certain embodiments disclosed herein include, but are not limited to, methods of modifying stem cells, or methods of administering modified stem cells to at least one biological tissue.
Abstract: The present application relates to extracellular vesicles (EVs) derived from gram-positive bacteria. In detail, the present application provides animal models of disease using extracellular vesicles derived from gram-positive bacteria, provides a method for screening an active candidate substance which is capable of preventing or treating diseases through the animal models of disease, provides vaccines for preventing or treating diseases caused by extracellular vesicles derived from gram-positive bacteria, and provides a method for diagnosing the causative factors of diseases caused by gram-positive bacteria using extracellular vesicles.
Type:
Grant
Filed:
August 26, 2010
Date of Patent:
March 3, 2015
Assignee:
Aeon Medix Inc.
Inventors:
Yong Song Gho, Yoon Keun Kim, Eun Young Lee, Sung Wook Hong, Ji Hyun Kim, Seng Jin Choi
Abstract: The invention provides a method of isolating dermal stem cells, having the steps of subjecting cells separated from the skin by enzyme treatment to suspension culture, and isolating cells positive for stem cell markers from the cultured cells.
Abstract: The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.